Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi Sells 2,274 Shares

Blueprint Medicines Co. (NASDAQ:BPMC) COO Christina Rossi sold 2,274 shares of Blueprint Medicines stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $110.14, for a total value of $250,458.36. Following the completion of the sale, the chief operating officer now owns 67,109 shares of the company’s stock, valued at $7,391,385.26. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Christina Rossi also recently made the following trade(s):

• On Wednesday, December 18th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The stock was sold at an average price of $95.91, for a total transaction of $218,099.34.
• On Wednesday, November 27th, Christina Rossi sold 2,274 shares of Blueprint Medicines stock. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40.

Blueprint Medicines Price Performance

Shares of BPMC traded up $4.55 during mid-day trading on Thursday, reaching $115.63. 1,479,676 shares of the company’s stock were exchanged, compared to its average volume of 990,877. Blueprint Medicines Co. has a 52-week low of $72.24 and a 52-week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company has a 50-day simple moving average of $95.28 and a two-hundred day simple moving average of $95.48. The company has a market cap of $7.35 billion, a price-to-earnings ratio of -54.80 and a beta of 0.61.

Blueprint Medicines (NASDAQ:BPMC) last released its earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analyst estimates of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm’s quarterly revenue was up 126.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.20) EPS. On average, sell-side analysts predict that Blueprint Medicines Co. will post -3.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Blueprint Medicines

A number of hedge funds have recently made changes to their positions in the stock. R Squared Ltd purchased a new position in shares of Blueprint Medicines in the 4th quarter worth about $51,000. KBC Group NV increased its position in Blueprint Medicines by 63.9% during the 4th quarter. KBC Group NV now owns 2,625 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 1,023 shares in the last quarter. Fifth Third Bancorp raised its holdings in Blueprint Medicines by 207.5% in the fourth quarter. Fifth Third Bancorp now owns 3,075 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 2,075 shares during the period. SG Americas Securities LLC lifted its position in Blueprint Medicines by 69.7% during the fourth quarter. SG Americas Securities LLC now owns 4,277 shares of the biotechnology company’s stock valued at $373,000 after buying an additional 1,756 shares in the last quarter. Finally, Empirical Asset Management LLC purchased a new stake in Blueprint Medicines during the fourth quarter worth approximately $2,348,000.

Analyst Ratings Changes

BPMC has been the subject of a number of research analyst reports. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, November 15th. Wells Fargo & Company dropped their target price on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating on the stock in a research report on Thursday, October 31st. Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a research report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $122.72.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.